Physician
Sosa, Fernando
Sosa, Fernando was paid $2.29M by Medicaid between Aug 2018 and Dec 2024, across 52 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 32% of everything it billed.
33Billing provider infoSOSA, FERNANDO
LAREDO, TX 78041
LAREDO, TX 78041
33aNPI1760461099assigned 01/13/2006
33bProvider typePediatrics Physician
28Total paid$2.29M
24GClaims103,937
24DCodes billed52
24AFirst – last monthAug 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Texas
Rank by total paid#213 of 1,136
Median peer was paid$329K
This provider vs. median7.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 23 | $848.47 | |
| 2019 | 19 | $700.91 | |
| 2020 | 4,179 | $87K | |
| 2021 | 25,785 | $549K | |
| 2022 | 26,554 | $606K | |
| 2023 | 25,064 | $545K | |
| 2024incomplete | 22,313 | $501K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 32% | 20,518 | 16,938 | $735K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 14% | 4,197 | 4,144 | $330K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 12% | 3,596 | 3,414 | $270K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 9.2% | 2,563 | 2,517 | $212K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 9.0% | 19,150 | 8,951 | $205K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 6.2% | 1,569 | 1,539 | $142K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.9% | 1,844 | 1,762 | $90K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 3.6% | 6,422 | 3,056 | $82K |
| 99429 | 2.3% | 1,576 | 1,564 | $53K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.9% | 5,354 | 3,576 | $43K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | <1% | 419 | 404 | $22K |
| 99381 | <1% | 279 | 265 | $22K |
40 more codes
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,620 | $21K |
| 97802 | <1% | 6,701 | $20K | |
| 90461 | <1% | 6,453 | $20K | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 400 | $4K |
| 96161 | <1% | 1,783 | $4K | |
| 0072A | <1% | 92 | $4K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 44 | $3K |
| 0071A | <1% | 55 | $2K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 26 | $1K |
| 0001A | <1% | 80 | $1K | |
| 86580 | <1% | 100 | $801.08 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 49 | $686.88 |
| 0002A | <1% | 13 | $520.00 | |
| 97803 | <1% | 1,213 | $446.70 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 15 | $361.39 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 31 | $322.28 |
| 90686 | <1% | 2,369 | $17.52 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 50 | $7.50 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 31 | $1.59 |
| 90621 | <1% | 355 | $0.02 | |
| 90651 | <1% | 742 | $0.01 | |
| 90710 | 0% | 1,297 | $0.00 | |
| 90700 | 0% | 760 | $0.00 | |
| 91300 | 0% | 108 | $0.00 | |
| 90670 | 0% | 1,846 | $0.00 | |
| 90734 | 0% | 706 | $0.00 | |
| 90648 | 0% | 1,352 | $0.00 | |
| 90633 | 0% | 1,482 | $0.00 | |
| 90707 | 0% | 38 | $0.00 | |
| 90715 | 0% | 184 | $0.00 | |
| 90671 | 0% | 1,265 | $0.00 | |
| 90696 | 0% | 433 | $0.00 | |
| 90680 | 0% | 2,183 | $0.00 | |
| 90698 | 0% | 296 | $0.00 | |
| 90723 | 0% | 595 | $0.00 | |
| 90697 | 0% | 1,349 | $0.00 | |
| 91307 | 0% | 170 | $0.00 | |
| 90620 | 0% | 123 | $0.00 | |
| 90744 | 0% | 15 | $0.00 | |
| 90716 | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.